Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
38.6M
-
Shares change
-
+1.32M
-
Total reported value, excl. options
-
$390M
-
Value change
-
+$12.7M
-
Put/Call ratio
-
1.91
-
Number of buys
-
56
-
Number of sells
-
-62
-
Price
-
$10.09
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2020
158 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q3 2020.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.6M shares
of 49.6M outstanding shares and own 77.83% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (3.47M shares), FRED ALGER MANAGEMENT, LLC (3.33M shares), BlackRock Inc. (2.96M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.83M shares), STATE STREET CORP (2.82M shares), Camber Capital Management LP (2.56M shares), Camber Capital Management LP (2.56M shares), RENAISSANCE TECHNOLOGIES LLC (1.55M shares), Palo Alto Investors LP (1.37M shares), and ACADIAN ASSET MANAGEMENT LLC (1.35M shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.